Press Releases

Aug 31, 2020

Meridian Bioscience to Present at the H. C. Wainright 22nd Annual Global Investment Conference

Aug 07, 2020

Meridian Bioscience Reports Fiscal Third Quarter 2020 Operating Results – Best Quarter in Company History – Raises Full Year Guidance

Jul 28, 2020

Meridian Bioscience Announces New Board Member - Anthony Bihl

Jul 16, 2020

Meridian Bioscience to Hold Third Quarter 2020 Financial Results Conference Call on August 7, 2020

Jul 13, 2020

Meridian Bioscience Announces the Launch of a High-Sensitivity SARS-CoV-2 Nucleocapsid Antibody Pair for the Development of Rapid COVID-19 Antigen Assays

May 29, 2020

Meridian Bioscience to Participate in the 40th Annual William Blair Growth Stock Conference

May 26, 2020

Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month

May 20, 2020

Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics

May 08, 2020

Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products

May 06, 2020

Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay

Apr 30, 2020

Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience

Apr 27, 2020

Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply

Apr 16, 2020

Meridian Bioscience To Hold Second Quarter 2020 Financial Results Conference Call On May 8, 2020

Apr 14, 2020

Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

Apr 02, 2020

MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

Mar 16, 2020

Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

Mar 16, 2020

Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay

Feb 26, 2020

Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers

Feb 19, 2020

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

Feb 07, 2020

Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance

Innerpage

Meridian Bioscience to Present at the H. C. Wainright 22nd Annual Global Investment Conference

Meridian Bioscience Reports Fiscal Third Quarter 2020 Operating Results – Best Quarter in Company History – Raises Full Year Guidance

Meridian Bioscience Announces New Board Member - Anthony Bihl

Meridian Bioscience to Hold Third Quarter 2020 Financial Results Conference Call on August 7, 2020

Meridian Bioscience Announces the Launch of a High-Sensitivity SARS-CoV-2 Nucleocapsid Antibody Pair for the Development of Rapid COVID-19 Antigen Assays

Meridian Bioscience to Participate in the 40th Annual William Blair Growth Stock Conference

Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month

Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics

Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products

Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay

Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience

Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply

Meridian Bioscience To Hold Second Quarter 2020 Financial Results Conference Call On May 8, 2020

Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay

Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance